Daniela Allmer

Ms. Daniela Allmer

orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 November 2024 in Frontiers in Medicine
Verified
Journal Article
Open access
PDF file
DADaniela Allmer
Daniela Allmer
DRDiego Parada Rodriguez
Diego Parada Rodriguez
CAChristof Aigner
Christof Aigner
FLFranco Laccone
Franco Laccone
MNMato Nagel
Mato Nagel
GSGere Sunder-Plassmann
Gere Sunder-Plassmann
Autosomal-dominant polycystic kidney disease (ADPKD) is the most common inherited kidney disease and fourth leading cause for renal replacement therapy worldwide. Disease progression is tightly linked to genotype, however, factors like genetic modifiers and environmental factors are responsible for a high phenotypic variability within- as well as between families. Individual’s risk of progression to kidney failure is assessed using prediction- or risk-assessment tools such as the predicting renal outcomes in ADPKD score (PROPKD score) and the Mayo Imaging Classification (MIC). The PROPKD score encompasses genetic and phenotypic parameters, while the MIC relies on renal imaging, height, and age of patients. Both methods categorize patients into low-risk, intermediate-risk, and high-risk for progression to kidney failure. In this retrospective, cross-sectional study, we calculated the risk of progression to kidney failure in our population and analyzed the agreement between the methods in three separate models with alternating stratification of MIC risk categories. We found a mismatch for risk assessment between the respective risk categories, indicating that the PROPKD score and MIC should not be used interchangeably. Preferably, the MIC should be used as a base for risk assessment and may be enhanced by genotypic and phenotypic information.

6 October 2025 in Wiener klinische Wochenschrift
Verified
Journal Article
Closed access
PDF file
SSSophie Henriette Schmidt
Sophie Henriette Schmidt
DRDiego Parada Rodriguez
Diego Parada Rodriguez
DADaniela Allmer
Daniela Allmer
OSOliver Schlager
Oliver Schlager
SMSylvia Metz-Schimmerl
Sylvia Metz-Schimmerl
GSGere Sunder-Plassmann
Gere Sunder-Plassmann

20 March 2026 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
CGConstantin Gatterer
Constantin Gatterer
DADaniela Allmer
Daniela Allmer
DBDietrich Beitzke
Dietrich Beitzke
Senta GrafSenta Graf
Senta Graf
PHPhilipp Hohensinner
Philipp Hohensinner
Max LenzMax Lenz
Max Lenz
Background/Objectives: Fabry disease (FD) is a lysosomal storage disorder characterized by progressive renal and cardiac involvement and an increased burden of cardiovascular and cerebrovascular events. While cardiac magnetic resonance imaging (CMR) has significantly advanced structural assessment, circulating biomarkers reflecting disease-related cardiac manifestations remain incompletely understood. We therefore investigated adiponectin and leptin, two adipokines involved in inflammatory, metabolic, and fibrotic pathways, in relation to cardiac involvement and analyzed long-term lipid trajectories in FD. Methods: This longitudinal observational study included 49 patients with FD with 149 study visits. Circulating adiponectin, leptin, NT-proBNP, and conventional lipid parameters were assessed longitudinally and stratified by FD-specific therapy status and sex. Multivariable linear regression was performed to evaluate independent associations with log-transformed NT-proBNP values. Results: Adiponectin was positively associated with NT-proBNP, reflecting cardiac involvement, independent of age, sex, BMI, and eGFR (p < 0.001). Higher adiponectin levels were observed in patients with left ventricular hypertrophy or low T1 and those with fibrosis, detected by CMR (p = 0.009 and p < 0.001, respectively). This association was mainly seen in patients receiving FD-specific therapy, raising the question of whether this reflects underlying organ involvement or treatment effects. Leptin demonstrated weaker, inverse associations. Adiponectin, leptin, Triglycerides, total cholesterol, and HDL- and LDL-cholesterol levels remained stable over long-term follow-up, irrespective of FD-specific therapy or sex. Conclusions: In FD, adiponectin appears to be associated with cardiac involvement, and conventional lipid parameters remained unchanged over time. These findings suggest that alterations in adipokines, rather than progressive dyslipidemia, may reflect disease-related cardiac manifestations.

30 October 2026 in Rare Disease and Orphan Drugs Journal
Verified
Journal Article
Open access
PDF file
CPChristopher Paschen
Christopher Paschen
DADaniela Allmer
Daniela Allmer
ASAlice Schmidt
Alice Schmidt
GSGere Sunder-Plassmann
Gere Sunder-Plassmann